Company Overview
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -40.13% |
| 6 Months: | -67.54% |
| 3 Months: | -69.48% |
| 1 Month: | -54.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)23.71 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 95.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 24 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SKYE Skye Bioscience, Inc. PHARMA | 1.88 | -0.18 | $8.32M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Apr 2014 | Jun 2014 | Jul 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.76M | 18.24M | 13.26M | 14.90M | 12.67M |
| Operating Income | -13.43K | -142.92K | 4.05K | -857.61K | -909.83K | -1.36M | -896.29K | -1.22M | -1.48M | -856.15K | -1.38M | -730.93K | -761.63K | -1.25M | -1.08M | -1.05M | -1.52M | -1.77M | -1.50M | -2.21M | -1.22M | -1.54M | -1.74M | -1.83M | -1.82M | -2.89M | -3.22M | -2.92M | -3.10M | -2.84M | -24.71M | -6.15M | -8.41M | -4.97M | - | -11.76M | -18.24M | -13.26M | -14.90M | -12.67M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.92M | -17.43M | -12.58M | -14.26M | -12.33M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.45K | 0 | 0 | 0 | 2.20K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.10M | -17.62M | -12.75M | -14.44M | -12.51M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.00K | 3.40K | 0 | 0 | 0 |
| Net Income | -13.51K | -142.92K | 7.76K | -858.52K | -910.23K | -2.06M | -1.18M | -1.69M | 573.09K | -945.27K | -1.28M | -702.76K | -480.13K | -8.21M | -2.66M | -2.10M | -14.77M | 15.91M | -4.93M | -2.34M | -1.42M | -1.30M | -2.16M | -2.02M | -1.82M | -3.04M | -3.42M | -3.13M | -5.17M | -3.11M | -24.95M | -5.02M | -7.90M | -3.90M | - | -11.10M | -17.62M | -12.75M | -14.44M | -12.51M |
| Diluted EPS | - | - | - | - | - | -0.13 | - | - | 0.03 | -0.05 | -0.09 | -0.02 | -0.02 | -0.09 | -0.02 | -0.02 | -0.11 | 0.08 | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 | -1.58 | -1.37 | -0.80 | -3.17 | -0.18 | -0.20 | -0.10 | - | -0.28 | -0.44 | -0.32 | -0.36 | -0.32 |
| R&D Expense | - | - | - | 195.00K | 37.20K | 43.37K | 152.29K | 135.36K | 459.96K | 80.53K | 92.10K | 60.65K | 88.55K | 25.00K | - | 67.29K | 320.99K | 688.04K | 513.00K | 799.61K | 428.53K | 346.22K | 609.66K | 880.67K | 327.73K | 1.27M | 1.43M | 1.78M | 1.18M | 1.79M | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2012 | Oct 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 12.11M | 13.67M | 36.43M | 58.16M |
| Operating Income | 4.12K | -7.24K | -120.40K | -2.73M | -4.32M | -4.47M | -3.86M | -4.69M | -6.63M | -6.29M | - | -12.11M | -13.67M | -36.43M | -58.16M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -18.70M | -36.62M | -25.29M | -55.20M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 663.77K | 897.21K | 967.60K | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -19.47M | -37.64M | -26.56M | -55.92M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 6.74K | 3.60K | 10.07K | 5.40K |
| Net Income | 4.51K | -3.78K | -120.40K | -2.73M | -4.84M | -3.18M | -3.09M | -19.19M | 1.05M | -6.56M | - | -19.48M | -37.64M | -26.57M | -55.92M |
| Diluted EPS | - | - | - | - | - | -0.17 | -0.11 | -0.16 | -0.05 | -0.03 | - | -8.77 | -5.37 | -0.73 | -1.41 |
| R&D Expense | - | - | - | 227.50K | 576.09K | 939.04K | 311.30K | 329.97K | 2.24M | 1.94M | 2.93M | 6.01M | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2011 | Oct 2012 | Dec 2012 | Oct 2013 | Dec 2013 | Sep 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 42.88K | - | 145.69K | - | - | 348.35K | 3.51M | 323.36K | 557.22K | 1.96M | 2.00M | 2.67M | - | 9.11M | 11.94M | 72.76M | 28.31M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.94M | 11.65M | 70.83M | 27.09M |
| Cash & Equivalents | 13.91K | 26.40K | - | 52.19K | - | 1.03M | 207.33K | 3.22M | 64.82K | 259.95K | 1.85M | - | - | - | 1.24M | 1.26M | 68.42M | 5.88M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.12K | 158.24K | 5.07K | 10.47K |
| Total Liabilities | - | 4.33K | - | 62.32K | 182.15K | - | 801.89K | 3.04M | 1.77M | 1.36M | 17.52M | 1.45M | 2.22M | - | 12.12M | 14.07M | 4.61M | 8.29M |
| Current Liabilities | - | 4.33K | - | 62.32K | 182.15K | - | 801.09K | 581.86K | 661.96K | 805.97K | 15.94M | 970.82K | 787.20K | - | 12.12M | 13.90M | 4.34M | 8.21M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.98M | 4.62M | 455.59K | 273.65K |
| Total Equity | 25.95K | 38.56K | -61.75K | 83.38K | -182.15K | - | -453.55K | -892.20K | -2.91M | -3.57M | -15.56M | 548.06K | 450.79K | - | -3.01M | -2.13M | 68.15M | 20.02M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.65M | 12.35M | 30.97M | 33.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -3.33M | -3.94M | -6.03M | -6.05M | - | -12.74M | -13.95M | -25.24M | -43.06M |
| Investing Cash Flow | - | - | - | - | -19.65K | -4.38K | - | -7.23K | - | 5.21M | 6.60M | -245.62K | -19.50M |
| Financing Cash Flow | - | - | - | - | 3.51M | 5.54M | 6.00M | 6.70M | - | -208.79K | 16.44M | 83.56M | 29.57K |
| Capital Expenditure | -49.12K | -23.26K | -1.98K | -11.12K | -19.65K | -4.38K | - | -7.23K | - | -28.06K | -12.55K | -1.60M | -6.31K |
| Free Cash Flow | - | - | - | - | -3.35M | -3.95M | - | -6.06M | - | -12.77M | -13.96M | -26.84M | -43.07M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -7.74M | 9.09M | 58.08M | -62.53M |
Ratios (Annual)
Figures in %.
| Metric | Oct 2012 | Oct 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 11.7% | -4.5% | 66.1% | 602.8% | 542.6% | 109.1% | 86.7% | 123.3% | 191.9% | -1,455.4% | - | 647.6% | 1,765.9% | -39.0% | -279.3% |
| ROCE % | 10.7% | -8.7% | - | 603.4% | -147.4% | 1,320.3% | 1,551.4% | 33.6% | -646.5% | -333.7% | - | 402.5% | 697.3% | -53.2% | -289.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | 5AM Venture Management, LLC | 27.33% | 1.21M | $2.14M |
| 2 | Versant Venture Management, LLC | 5.67% | 250.96K | $442.95K |
| 3 | Baker Bros. Advisors, LP | 4.45% | 196.91K | $347.54K |
| 4 | Vanguard Capital Management LLC | 2.16% | 95.48K | $168.53K |
| 5 | Sphera Funds Management Ltd. | 1.92% | 84.87K | $149.79K |
| 6 | Platinum Investment Management Ltd | 0.66% | 29.14K | $51.43K |
| 7 | Blackrock Inc. | 0.66% | 29.11K | $51.38K |
| 8 | Geode Capital Management, LLC | 0.62% | 27.26K | $48.11K |
| 9 | Millennium Management Llc | 0.56% | 24.82K | $43.80K |
| 10 | Vanguard Fiduciary Trust Co | 0.29% | 13.03K | $23.00K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SKYE
Skye Bioscience Inc (SKYE) Stock Price, Quote, News & History - Benzinga
<a href="https://news.google.com/rss/articles/CBMiS0FVX3lxTE90YXY3YkZwcFpmR29BeG8tYTk2VEF0ZkYxVmQ0cTBMQWV4MFVHRDlCS1RuNHJDcGM3cENBVGJEaEN2UGNHZFdOUXgyUQ?oc=5" target="_blank">Skye Bioscience Inc (SKYE) Stock Price, Quote, News & History</a>…
Skye Bioscience (SKYE) insider funds sell 375,840 shares at $0.32–$0.41 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPQlZQTkRRcUhVSVkyX0d0WXZES05peTFzQjdVSm1Bcm12RElTYk4wUHVyUUQ0VmtrNXRkRTA0ZnJ5T1NHYkFEOG9rWFJVX2VUQUVwU0pUYm5RNWQwVGFFSDRrXzNWdlVINUZZbnBFTHUyTk5Vc2tnVkJlVmNQdE4yX0Vndl9wVmE4WFg1Yk…
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxNaGNWUVdJaGxlaFFaV1N3bWd1UUxzUFBpNThJbTNnQ3J0X3NRcXpnMEpTdWxmVXZ4TlJnZk93RXhGZTVGZ1RBWmUzeW1hQ3dIS21ETEcxdC0tY216alBVVVhpbjlQUjQzSF95a09LTGlNYjNlcnh2Umd0MVpPWThNWXVGZDIwRWVmQ1lJWn…
5am Partners VII, LLC sells $140,313 of Skye Bioscience stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNYWE4UHpHZXdZT1MxUlB0YjE0ODVJWV9XekY5em0yOEt6S3N0R2x6WXFiS2plQ0NITjNPQUR1QmxDak12RXpPQmYwWWszSzQ5eVIzSnlLVnRBTUhwQVlVZjhKa1JaNllmNGxxcHI1X1RIMGkyQ3g3NUJoM0hzSWxtWUJEZGlPSWFEMXpla1…
Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTFBVcmtRZG1zbVF0b2Q2RkFDVTdjTkR5ZVE2TExJam1pVE9TZllSbll3U3p5YWEtN1FEU1BiVkJIR0hPTlIzS1RFU3ZYUTkyZzlta1BfU3Nvc2s?oc=5" target="_blank">Skye Bioscience (SKYE) Shares Rise 6% After Hour…
Insider Sale: Director at $SKYE Sells 46 Shares | SKYE Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxOcUx2OEZuVzhvYWdhQnZhOHdYZXRoN1Y3dldCRnNWUzN5SlBnXzcwY044Y2FMUjBZTXRTR3RGWkFJcjJRd1lCcFFZQ2VfRDRFMlVkYk1QZi12ZlozalRRZWNHbHowMnhoajV6Z1pKVUlBbWo0Ylh2MGloamtOU213RFBJdENXYzBySlBTeA…
SKYE — Frequently Asked Questions
What is the current share price of Skye Bioscience, Inc. (SKYE)?
As of 2026-09-19 21:16 PDT, Skye Bioscience, Inc. (SKYE) trades at $1.88 on NasdaqCM. Its 52-week range is $1.68 to $38.00.
What is the market capitalisation of SKYE?
Skye Bioscience, Inc. (SKYE) has a market capitalisation of $8.32M on NasdaqCM.
What is the P/E ratio of SKYE?
SKYE trades at a trailing price-to-earnings (P/E) ratio of -0.18. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -15.62.
Is SKYE a good stock to buy?
This page provides a data-driven analysis of Skye Bioscience, Inc. (SKYE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.